ATE321131T1 - Mutierte klasse-i-mhc-moleküle - Google Patents

Mutierte klasse-i-mhc-moleküle

Info

Publication number
ATE321131T1
ATE321131T1 AT98942169T AT98942169T ATE321131T1 AT E321131 T1 ATE321131 T1 AT E321131T1 AT 98942169 T AT98942169 T AT 98942169T AT 98942169 T AT98942169 T AT 98942169T AT E321131 T1 ATE321131 T1 AT E321131T1
Authority
AT
Austria
Prior art keywords
mhc molecules
mutated class
class
mutated
beta2
Prior art date
Application number
AT98942169T
Other languages
English (en)
Inventor
David N Garboczi
Juergen B Walter
Original Assignee
David N Garboczi
Juergen B Walter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David N Garboczi, Juergen B Walter filed Critical David N Garboczi
Application granted granted Critical
Publication of ATE321131T1 publication Critical patent/ATE321131T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Removal Of Specific Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT98942169T 1997-08-29 1998-08-20 Mutierte klasse-i-mhc-moleküle ATE321131T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/920,413 US6248564B1 (en) 1997-08-29 1997-08-29 Mutant MHC class I molecules

Publications (1)

Publication Number Publication Date
ATE321131T1 true ATE321131T1 (de) 2006-04-15

Family

ID=25443710

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98942169T ATE321131T1 (de) 1997-08-29 1998-08-20 Mutierte klasse-i-mhc-moleküle

Country Status (5)

Country Link
US (1) US6248564B1 (de)
EP (1) EP1017799B1 (de)
AT (1) ATE321131T1 (de)
DE (1) DE69833949T2 (de)
WO (1) WO1999011775A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521197B2 (en) 1998-06-05 2009-04-21 Alexis Biotech Limited Method for producing cytotoxic T-cells
US7264965B2 (en) 1998-06-05 2007-09-04 Alexis Biotech Limited Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
GB2339782A (en) * 1998-06-05 2000-02-09 Philip Michael Savage Chimeric protein complexes comprising HLA class I antigens
FR2798128B1 (fr) * 1999-09-06 2001-11-16 Inst Nat Sante Rech Med Moyens de detection et de purification de populations lymphocytaires t cd8+ specifiques de peptides presentes dans le contexte hla
US20040209314A1 (en) 1999-09-06 2004-10-21 Institut National De La Sante Et De La Recherche Medicale France Means for detection and purification of CD8+ T lymphocyte populations specific to peptides presented in the context of HLA
EP2316950A1 (de) * 2000-03-27 2011-05-04 Technion Research and Development Foundation, Ltd. Einkettige Haupthistokompatibilitätskomplexe der Klasse I (MHC-I), kodierende Konstrukte und Methoden ihrer Erzeugung
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US8022190B2 (en) * 2001-06-19 2011-09-20 Technion Research & Development Foundation Ltd. Immuno-molecules containing viral proteins, compositions thereof and methods of using
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
AU2003284162A1 (en) * 2002-10-28 2004-05-25 Genzyme Corporation Anti-hiv (sl9) compounds
US20050025771A1 (en) * 2003-03-04 2005-02-03 Greenville Hospital System Antitumor agents comprising a targeting portion and an immune response triggering portion
US20040210037A1 (en) * 2003-03-28 2004-10-21 Vaccinex, Inc. Targeted MHC class I alpha3 vaccine delivery systems
US20050042218A1 (en) * 2003-07-10 2005-02-24 Vaccinex, Inc. MHC class I - peptide-antibody conjugates with modified beta2-microglobulin
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
RU2412947C2 (ru) * 2004-09-23 2011-02-27 Дженентек, Инк. Антитела, сконструированные на основе цистеинов, и их конъюгаты
WO2007085266A1 (en) * 2006-01-30 2007-08-02 Dako Denmark A/S High-speed quantification of antigen specific t-cells in whole blood by flow cytometry
EP2007428A2 (de) 2006-04-05 2008-12-31 Genentech, Inc. Verfahren zur verwendung von boc/cdo zur modulation der hedgehog-signalisierung
CA2652538C (en) * 2006-05-19 2016-06-28 Teva Pharmaceutical Industries, Ltd. Fusion proteins, uses thereof and processes for producing same
GB2442048B (en) * 2006-07-25 2009-09-30 Proimmune Ltd Biotinylated MHC complexes and their uses
US8617531B2 (en) * 2006-12-14 2013-12-31 Bolder Biotechnology, Inc. Methods of making proteins and peptides containing a single free cysteine
EP2112930B1 (de) * 2007-02-21 2017-01-11 Vaccinex, Inc. Modulation der nkt-zellaktivität mit antigenbeladenen cdid-molekülen
EP2155782A2 (de) 2007-03-26 2010-02-24 Dako Denmark A/S Mhc-peptid-komplexe und anwendungen davon bei infektionskrankheiten
EP2167537A2 (de) 2007-07-03 2010-03-31 Dako Denmark A/S Zusammengestellte verfahren für die analyse und sortierung von proben
AU2008276128B2 (en) 2007-07-16 2013-10-10 Genentech, Inc. Humanized anti-CD79b antibodies and immunoconjugates and methods of use
CL2008002085A1 (es) 2007-07-16 2008-11-21 Genentech Inc Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b
EP2197908A2 (de) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc-multimere in tuberkulose-diagnostika, -impfstoff und therapeutika
WO2009052249A1 (en) * 2007-10-19 2009-04-23 Genentech, Inc. Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
CA2711736A1 (en) 2008-01-18 2009-07-23 Medimmune, Llc Cysteine engineered antibodies for site-specific conjugation
HUE029869T2 (en) * 2008-01-31 2017-04-28 Genentech Inc Anti-CD79B antibodies and immunoconjugates, as well as application procedures
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
WO2010009735A2 (en) * 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) * 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
KR101928684B1 (ko) 2009-01-08 2018-12-12 앨버트 아인슈타인 컬리지 오브 메디신, 인크. 세포벽 결합 세라미드 유사 당지질을 갖는 박테리아 백신 및 이의 용도
WO2010106535A1 (en) 2009-03-15 2010-09-23 Technion Research And Development Foundation Ltd. Soluble hla complexes for use in disease diagnosis
CN102471380B (zh) 2009-04-01 2015-01-14 霍夫曼-拉罗奇有限公司 抗FcRH5抗体和免疫偶联物及使用方法
CA2756988A1 (en) 2009-04-01 2010-10-07 Genentech, Inc. Anti-fcrh5 antibodies and immunoconjugates
EP2711018A1 (de) 2009-06-22 2014-03-26 MedImmune, LLC Manipulierte Fc-Regionen für standortspezifische Konjugation
TWI537383B (zh) 2009-11-30 2016-06-11 建南德克公司 診斷及治療腫瘤之組合物及方法
SG183335A1 (en) 2010-02-23 2012-09-27 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
EP3372617B1 (de) 2010-04-02 2024-07-24 Amunix Pharmaceuticals, Inc. Bindungsfusionsproteine, bindungsfusionsproteinarzneimittelkonjugate, xten-arzneimittelkonjugate sowie verfahren zur herstellung und verwendung davon
SG185027A1 (en) 2010-05-03 2012-11-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
CN114246952A (zh) 2010-06-08 2022-03-29 基因泰克公司 半胱氨酸改造的抗体和偶联物
EP3406347A3 (de) 2012-02-27 2019-02-13 Amunix Operating Inc. Xten-konjugat-zusammensetzungen und verfahren zur herstellung davon
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
AR096687A1 (es) 2013-06-24 2016-01-27 Genentech Inc Anticuerpos anti-fcrh5
RS60453B1 (sr) 2013-12-17 2020-07-31 Genentech Inc Anti-cd3 antitela i postupci upotrebe
EP3388449A3 (de) 2014-09-12 2018-10-24 F. Hoffmann-La Roche AG Cystein-manipulierte antikörper und konjugate
RS60349B8 (sr) 2014-09-23 2022-10-31 Hoffmann La Roche Postupak upotrebe anti-cd79b imunokonjugata
CN107849132B (zh) 2015-06-16 2022-03-08 豪夫迈·罗氏有限公司 人源化的和亲和力成熟的针对FcRH5的抗体和使用方法
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
EP3497121A2 (de) * 2016-08-11 2019-06-19 Kite Pharma Eu B.V. Verfahren zur herstellung und verwendung von löslichen mhc-molekülen
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
EP3719033A1 (de) * 2019-04-02 2020-10-07 imusyn GmbH & Co. KG Stabilisiertes mhc i
US20220273810A1 (en) 2019-07-08 2022-09-01 Imcare Biotech, Llc Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use
CN114901699A (zh) 2019-09-11 2022-08-12 英凯尔生物科技有限责任公司 抗丝氨酸蛋白酶抑制剂kazal(spik)抗体的表位
BR112022011824A2 (pt) 2019-12-18 2022-08-30 Teneofour Inc Anticorpos de cadeia pesada que se ligam a cd38
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1979000160A1 (en) 1977-09-28 1979-04-05 Nat Res Dev Improvements in or relating to immunological preparations
JPS56500298A (de) 1979-03-27 1981-03-12
US4698420A (en) 1985-02-25 1987-10-06 Xoma Corporation Antibody hybrid molecules and process for their preparation
US5153265A (en) 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5130297A (en) 1988-06-23 1992-07-14 Anergen, Inc. Conjugates useful in ameliorating autoimmunity MHC-II-peptide
DE3825615A1 (de) 1988-07-28 1990-02-01 Behringwerke Ag Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung
US5635363A (en) * 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells

Also Published As

Publication number Publication date
WO1999011775A1 (en) 1999-03-11
US6248564B1 (en) 2001-06-19
DE69833949D1 (de) 2006-05-11
DE69833949T2 (de) 2007-02-22
EP1017799B1 (de) 2006-03-22
EP1017799A1 (de) 2000-07-12
EP1017799A4 (de) 2004-08-04

Similar Documents

Publication Publication Date Title
DE69833949D1 (de) Mutierte klasse-i-mhc-moleküle
DE60010098D1 (de) 28-epirapaloge
DE59903442D1 (de) Azidfreie, gaserzeugende Zusammensetzung
ATE296105T1 (de) Iminbildende polysaccharide, deren herstellung und verwendung als zusatzmittel und immunstimulierende mittel
DE69730202D1 (de) Azidfreie, gaserzeugende zusammensetzungen
CY1106789T1 (el) Γενικος φορεας για στοχευση μοριων σε κυτταρα που εκφραζουν gb3 υποδοχεα
PT996668E (pt) Composicoes aquosas termofixas
DE122004000025I2 (de) Borons{ure-und-esterverbindungen, deren Systhese und Verwendungen
DE69329735D1 (de) Peptid-kohlenwasserstoff konjugate, welche t-zell immunität bewirken
SE9702773D0 (sv) Novel compounds
DK1404377T3 (da) Forbedrede chelatorkonjugater
BG107220A (en) Antitumoral ecteinascudin derivatives
ES2175734T3 (es) Composiciones de lavado y de acondicionamiento a base de silicona y de goma de galactomanano hidrofoba.
CY1108526T1 (el) Εμβολια εναντι καρκινων
DK0942754T3 (da) Konjugater anvendelige til behandlingen af prostatacancer
NO20015785D0 (no) I dets vesentlige oljefrie cyklosporinsammensetninger
DE19981911T1 (de) Gasbildende Zusammensetzung
DE59902827D1 (de) Azidfreie, gaserzeugende Zusammensetzung
NO20031860D0 (no) Kahalaolid F
DE60315827D1 (de) Verbesserte polysaccharid- und glykokonjugat-vakzine
DE50010265D1 (de) Azidfreie gaserzeugende Zusammensetzung
ATE280588T1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
BG106316A (en) Ambroxol-containing lozenge
ES2156021T3 (es) Composiciones que comprenden un derivado de dibenzoilmetano y un polimero poliamina.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties